Dr. Brian J. Copeland, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 86
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of South Carolina School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
LA license 201433 -
Psychiatry Physician
LA license 201433
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- East Jefferson General Hospital Metairie, LA
- University Medical Center New Orleans New Orleans, LA
- Touro Infirmary New Orleans, LA
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 220
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 60 | 40 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in New Orleans, LA | 159 |
| Memantine Hcl Other prescribers in New Orleans, LA | 81 |
| Donepezil Hcl Other prescribers in New Orleans, LA | 75 |
| Rytary (carbidopa/levodopa) Other prescribers in New Orleans, LA | 64 |
| Botox (onabotulinumtoxina) | 60 |
| Gabapentin Other prescribers in New Orleans, LA | 37 |
| Clonazepam Other prescribers in New Orleans, LA | 35 |
| Topiramate Other prescribers in New Orleans, LA | 30 |
| Primidone Other prescribers in New Orleans, LA | 30 |
| Quetiapine Fumarate Other prescribers in New Orleans, LA | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 83 payments worth $4,099 in total to this clinician.
| Ipsen Innovation | $1,879 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $481 |
| AbbVie Inc. | $392 |
| Eisai Inc. | $316 |
| UCB, Inc. | $215 |
| Neurocrine Biosciences, Inc. | $164 |
| Neurelis, Inc. | $126 |
| Otsuka America Pharmaceutical, Inc. | $125 |
| Food and Beverage | $2,457 |
|---|---|
| Travel and Lodging | $1,642 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Innovation Jun 18, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $1,407 |
| Ipsen Innovation Jun 17, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $236 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $21,073 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06625060 - A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
Ipsen Pharma Sas · Completed · NCT04936542
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.